{'fraction_non_alphanumeric': 0.03694267515923567, 'fraction_numerical': 0.0, 'mean_word_length': 5.442622950819672, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non‐D and non‐K‐alloimmunized pregnancies

Pregnant women are routinely screened for red blood cell (RBC) antibodies early in pregnancy. If RBC‐alloantibodies are detected, repeated laboratory testing is advised to timely identify pregnancies at high risk for severe hemolytic disease of the fetus and newborn (HDFN). We assessed for RBC alloantibodies, other than anti‐D or anti‐K, cut‐offs for the titer and the antibody dependent cellular cytotoxicity (ADCC) test to select high‐risk cases. To advise on test repeat intervals, and to avoid unnecessary testing, we evaluated the chance for exceeding the cut‐offs for Rh antibodies other than anti‐D, Jk, Fy, and S/s antibodies.